Publication | Closed Access

Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study)

Metabolic SyndromeDiabetes ManagementSpotlight StudyMedicineInsulin ManagementDiabetesType 2PharmacotherapyDiabetes MellitusPharmacologyJapanese Patients